Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Last Updated: February 3, 2023

Details for Patent: 7,309,707

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 7,309,707 protect, and when does it expire?

Patent 7,309,707 protects SPIRIVA and is included in one NDA.

Protection for SPIRIVA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-seven patent family members in thirty-seven countries.

Summary for Patent: 7,309,707
Title:Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
Abstract:The invention relates to a crystalline micronisate of (1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.)-7-[(hydroxydi-2-thienylacetyl- )oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[,4]nonane-bromide, processes for preparing it and its use for preparing a pharmaceutical composition, particularly for preparing a pharmaceutical composition with an anticholinergic activity.
Inventor(s): Bender; Helmut (Wiesbaden, DE), Graebner; Hagen (Ingelheim, DE), Schindler; Konrad (Ingelheim, DE), Trunk; Michael (Ingelheim, DE), Walz; Michael (Bingen, DE)
Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim, DE)
Application Number:10/385,175
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,309,707
Patent Claim Types:
see list of patent claims
Formulation; Compound; Process; Device;

Drugs Protected by US Patent 7,309,707

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Boehringer Ingelheim SPIRIVA tiotropium bromide POWDER;INHALATION 021395-001 Jan 30, 2004 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,309,707

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany102 12 264Mar 20, 2002

International Family Members for US Patent 7,309,707

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 039017 See Plans and Pricing
Austria 369365 See Plans and Pricing
Australia 2003212327 See Plans and Pricing
Brazil 0308513 See Plans and Pricing
Brazil PI0308513 See Plans and Pricing
Canada 2479652 See Plans and Pricing
China 100368410 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.